August 15, 2014: Dr. Jorge Castillo, Bing Center for Waldenstrom’s Macroglobulinemia presented his latest analysis of survival trends in WM at the 8th International Workshop on WM and Symposium on Multiple Myeloma (IWWM-8). His findings were as follows: Based on current knowledge, it was unclear if the prognosis of patients with Waldenström’s Macroglobulinemia was improving. Two recent studies from Europe provided disparate results. On one hand, a Greek study showed that the outcomes of patients with Waldenström’s had not improved in the last decade despite of the advent of novel therapies such as rituximab and bortezomib. On the other hand, a larger Swedish study showed the survival of patients with Waldenström’s had improved in the last decade. Inspired on this apparent discrepancy, Bing Center investigators conducted the largest population-based study to date to identify survival trends in patients with Waldenström’s within the United States. The results of this study have been recently released in Blood, the journal of the American Society of Hematology.
SUNNYVALE, Calif., Oct. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on data from a Phase 2 study evaluating the use of IMBRUVICA® (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM), which was led by Dr. Steven Treon from the Dana-Farber Cancer Institute. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
The WM Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Plasma cell regulatory pathways in WM. In recent studies, we have attempted to dissect the molecular mechanisms which prevent WM cells from fully differentiating into plasma cells. Ordinarily, B-cells mature in a defined manner passing through the mature B-cell stage to lymphoplasmacytic cells, and then onto mature plasma cells. Mature plasma cells make antibodies that serve to protect us against pathogens, and typically include the IgA and IgG antibodies.